Therapeutic Research in Multiple Myeloma

This study is currently recruiting participants. (see Contacts and Locations)
Verified August 2014 by University of Arkansas
Sponsor:
Information provided by (Responsible Party):
University of Arkansas
ClinicalTrials.gov Identifier:
NCT00572338
First received: December 11, 2007
Last updated: August 27, 2014
Last verified: August 2014
  Purpose

The purpose of this study is to learn how myeloma cells grow and become a cancer, how to distinguish them from normal cells and how to eliminate these cells selectively.


Condition Intervention
Multiple Myeloma
Other: No drugs are involved

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: UARK 91-004 Therapeutic Research in Multiple Myeloma

Resource links provided by NLM:


Further study details as provided by University of Arkansas:

Biospecimen Retention:   Samples Without DNA
  • A bone marrow aspirate and biopsy
  • Blood
  • Fine Needle aspirates
  • Swabs of skin, throat, other sites

Estimated Enrollment: 5000
Study Start Date: August 2003
Estimated Study Completion Date: December 2015
Estimated Primary Completion Date: July 2015 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
patients with myeloma/related diseases Other: No drugs are involved
No treatment or drugs are involved in this research. Participating in this study requires that blood and bone marrow samples be obtained as a part of the diagnostic work-up or follow-up of participant's multiple myeloma. Bone marrow/peripheral blood samples will be collected at the same time for research purposes. Data will be collected including demographic information gathered from your medical record, including gender, date of birth, ethnicity, date of diagnosis, laboratory and pathology results, treatment protocols, dates of relapses, subsequent treatment protocols, and current treatments and medications.
Other Name: none, no treatment

Detailed Description:

Participating in this study will require that blood and bone marrow samples be obtained as a part of the diagnostic work-up or follow-up of your multiple myeloma. Bone marrow/peripheral blood/tissue samples will be collected for research purposes, as well as testing for genetic traits of Castleman's disease if you consent to this study. In addition, data will be collected including demographic information gathered from your medical record, including gender, date of birth, ethnicity, date of diagnosis, laboratory and pathology results, treatment protocols, dates of relapses, subsequent treatment protocols, and current treatments and medications.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population

Samples will be studied in the laboratory and in experimental animal models. These analyses and animal models may help to better understand multiple myeloma and to better select the appropriate treatment for all participants with multiple myeloma.

Criteria

Inclusion Criteria:

  • Any subject evaluated for a MIRT protocol

Exclusion Criteria:

  • Subjects who have not been evaluated for a MIRT protocol
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00572338

Contacts
Contact: Nathan Petty, MS 5015266990 ext 2435 pettynathanm@uams.edu

Locations
United States, Arkansas
University of Arkansas for Medical Sciences/MIRT Recruiting
Little Rock, Arkansas, United States, 72205
Sub-Investigator: Monica Grazziutti, MD         
Sub-Investigator: Frits van Rhee, MD         
Sub-Investigator: Jameel Muzaffar, MD         
Sub-Investigator: Senu Apewokin, MD         
Sub-Investigator: Shebli Atrash, MD         
Sub-Investigator: Aziz Bakhous, MD         
Sub-Investigator: Maurizio Zangari, MD         
Sub-Investigator: Aasiya Matin, MD         
Sub-Investigator: Rashid Khan, MD         
Sub-Investigator: Yogesh Jethava, MD         
Sponsors and Collaborators
University of Arkansas
Investigators
Principal Investigator: Bart Barlogie, MD, PhD UAMS Myeloma Institute for Research and Therapy
  More Information

No publications provided

Responsible Party: University of Arkansas
ClinicalTrials.gov Identifier: NCT00572338     History of Changes
Other Study ID Numbers: UARK 91-004
Study First Received: December 11, 2007
Last Updated: August 27, 2014
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Multiple Myeloma
Neoplasms, Plasma Cell
Neoplasms by Histologic Type
Neoplasms
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases
Paraproteinemias
Blood Protein Disorders
Hematologic Diseases
Hemorrhagic Disorders
Lymphoproliferative Disorders
Immunoproliferative Disorders
Immune System Diseases

ClinicalTrials.gov processed this record on September 22, 2014